Home > Research > Publications & Outputs > Supply chain risk management strategies in norm...

Electronic data

Links

Text available via DOI:

View graph of relations

Supply chain risk management strategies in normal and abnormal times: Policymakers’ role in reducing generic medicine shortages

Research output: Contribution to Journal/MagazineJournal articlepeer-review

Published
Close
<mark>Journal publication date</mark>22/03/2023
<mark>Journal</mark>International Journal of Physical Distribution & Logistics Management
Issue number2
Volume53
Number of pages25
Pages (from-to)206-230
Publication StatusPublished
Early online date28/09/22
<mark>Original language</mark>English

Abstract

Purpose
This paper links supply chain risk management to medicine supply chains to explore the role of policymakers in employing supply chain risk management strategies (SCRMS) to reduce generic medicine shortages.

Design/methodology/approach
Using secondary data supplemented with primary data, the authors map and compare seven countries' SCRMS for handling shortage risks in their paracetamol supply chains before and during the first two waves of the COVID-19 pandemic.

Findings
Consistent with recent research, the study finds that policymakers had implemented few SCRMS specifically for responding to disruptions caused by COVID-19. However, shortages were largely avoided since multiple strategies for coping with business-as-usual disruptions had been implemented prior to the pandemic. The authors did find that SCRMS implemented during COVID-19 were not always aligned with those implemented pre-pandemic. The authors also found that policymakers played both direct and indirect roles.

Research limitations/implications
Combining longitudinal secondary data with interviews sheds light on how, regardless of the level of preparedness during normal times, SCRMS can be leveraged to avert shortages in abnormal times. However, the problem is highly complex, which warrants further research.

Practical implications
Supply chain professionals and policymakers in the healthcare sector can use the findings when developing preparedness and response plans.

Social implications
The insights developed can help policymakers improve the availability of high-volume generic medicines in (ab)normal times.

Originality/value
The authors contribute to prior SCRM research in two ways. First, the authors operationalize SCRMS in the medicine supply chain context in (ab)normal times, thereby opening avenues for future research on SCRM in this context. Second, the authors develop insights on the role policymakers play and how they directly implement and indirectly influence the adoption of SCRMS. Based on the study findings, the authors develop a framework that captures the diverse roles of policymakers in SCRM.